Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
7.99
+0.07 (0.88%)
At close: Feb 21, 2025, 4:00 PM
8.27
+0.28 (3.53%)
After-hours: Feb 21, 2025, 7:59 PM EST
Novavax Revenue
Novavax had revenue of $84.51M in the quarter ending September 30, 2024, a decrease of -54.80%. This brings the company's revenue in the last twelve months to $885.19M, down -15.68% year-over-year. In the year 2023, Novavax had annual revenue of $983.71M, down -50.36%.
Revenue (ttm)
$885.19M
Revenue Growth
-15.68%
P/S Ratio
1.29
Revenue / Employee
$573,683
Employees
1,543
Market Cap
1.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
NVAX News
- 2 days ago - Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 - PRNewsWire
- 17 days ago - Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job - Reuters
- 17 days ago - Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary - CNBC
- 2 months ago - Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone - PRNewsWire
- 2 months ago - Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza - PRNewsWire
- 2 months ago - Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln - Reuters
- 2 months ago - Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million - PRNewsWire
- 3 months ago - Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha